Evaluation of HER2-low and ultralow status of advanced breast carcinomas
Monday, September 29, 2025 | 3-4pm CEST | 9-10 am EDT
Join this webinar to discover how digital pathology with AI evaluation is a more sensitive method for HER2-low assessment. Dr. Anikó Kovács (Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden) will present findings from a retrospective study on the HER2-low status of advanced breast carcinomas in core biopsies.
The aim of the study was to:
- compare the outcome of HER2 scoring using conventional microscopy, digital pathology, and AI.
- assess changes in HER2-low status in core biopsies, matching operation specimens, and their distant metastases.
Register for the webinar to learn more about the findings and how AI can help determine a more accurate HER2-low status, providing an exact percentage of each HER2 score within seconds with high accuracy.
Who should join?
- Pathologists involved in biomarker testing
- Oncologists relying on HER2-low status in treatment decisions
- Anyone involved in breast cancer diagnostics or therapeutic decision-making
- Anyone interested in using or developing AI models for image analysis in digital pathology
Speakers
Anikó Kovács, MD, PhD, Associate Professor, Pathologist, and Lecturer at Sahlgrenska University Hospital
- Has worked in research in Sweden for the past 23 years
- Breast cancer research at the Leicester University in the UK
- Research background also in Japan (Kitasato University) and Hungary
Rute Pedrosa, PhD, Senior Field Application Scientist, Aiforia Technologies
- Has worked at Aiforia for 2.5 years
- PhD at Erasmus University Rotterdam, focusing on the pathogenesis of brain metastatic disease